三种单吸管双支支气管扩展剂在治疗COPD的现实世界比较有效性
Jiaying Li1,2, Sophie Dell'Aniello1, Pierre Ernst1,2,3
1Centre for Clinical Epidemiology, Lady Davis Institute-Jewish General Hospital, Montreal, QC, Canada.
The European respiratory journal
|June 21, 2023
概括
建议在COPD治疗中使用单吸入器双支支气管扩展器. 维兰特罗尔-umeclidinium (VIL-UME) 在减少严重恶化方面表现出相似的有效性,与olodaterol-tiotropium (OLO-TIO) 和indacaterol-glycopyrronium (IND-GLY) 相比.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 建议在特定患者群体的COPD初始治疗中使用单吸入器双支支气管扩展剂.
- 通常使用的双重支气管扩展剂之间的有效性差异仍然不清楚.
研究的目的:
- 为了比较三种常见的单吸入式双支支气管扩展剂的实际有效性.
- 评估它们对COPD恶化和全因死亡率的影响.
主要方法:
- 一项使用英国临床实践研究数据链接 (2017-2020) 的真实世界队列研究.
- 之前没有吸入皮质类固醇的患者开始使用vilanterol-umeclidinium (VIL-UME),olodaterol-tiotropium (OLO-TIO) 或indacaterol-glycopyrronium (IND-GLY) 进行了比较.
- 倾向性得分权重被用于调整混因素.
主要成果:
- 与OLO-TIO (HR 0.91) 相比,VIL-UME显示中度或严重恶化的风险降低,与IND-GLY (HR 0.96) 相比,风险相似.
- 在VIL-UME和OLO-TIO或IND-GLY之间没有观察到严重恶化风险的显著差异.
- 与IND-GLY相比,使用VIL-UME的全因死亡率较低 (HR 0.82).
结论:
- 在现实世界COPD管理中,三种双重支气管扩展剂组合在预防严重恶化方面表现出类似的有效性.
- 在中度或重度恶化方面,VIL-UME和IND-GLY可能比OLO-TIO略有优势.
- VIL-UME可能会降低死亡风险,因此需要进一步调查.
相关概念视频
Inhaled Medications
321
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
321
COPD: Management Using Bronchodilators and Corticosteroids
255
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
255
Antiasthma Drugs: β2-Adrenoceptor Agonists
317
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
317
Drugs Used in Lower Respiratory Disorders: Overview
504
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
504
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Muscarinic Receptor Antagonists
348
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
348


